The Drug-Induced Cardiotoxicity Website and App
Frequency - Incidence
Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
Publications
Management of adverse effects/toxicity of ibrutinib.
Critical reviews in oncology/hematology. 2019;136:56-63
Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, Mahmood SS, Barac A, Groarke JD, Hayek SS, Dani S, Venesy D, Patten R, Nohria A
Ibrutinib-Associated Atrial Fibrillation.
JACC. Clinical electrophysiology. 2018;4(12):1491-1500
Ibrutinib-related atrial fibrillation: Therapeutic challenges.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2019;25(5):1258-1260
Cardiovascular Toxic Effects of Targeted Cancer Therapies.
The New England journal of medicine. 2016;375(15):1457-1467
Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
Blood. 2014;124(25):3829-30
Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A,
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
The New England journal of medicine. 2014;371(3):213-23